{"version":"1.0","type":"link","title":"TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial.","author_name":"Wang S 외","author_url":"https://prs-insight.online/author/Wang%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/91542","thumbnail_width":1200,"thumbnail_height":630}